Targeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunity
Authors:
Open Access
- 18 January 2026
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 246, 117721
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Developing New Strategies to Construct Pseudo-natural Macrocycles for Undruggable TargetsAccounts of Chemical Research, 2025
- Contemporary trends in targeted protein degradation for neurodegenerative diseasesEuropean Journal of Medicinal Chemistry, 2025
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC DegradersJournal of Medicinal Chemistry, 2025
- Targeted degradation of membrane and extracellular proteins with LYTACsActa Pharmacologica Sinica, 2024
- Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directionsCancer Immunology, Immunotherapy, 2024
- Emerging phagocytosis checkpoints in cancer immunotherapySignal Transduction and Targeted Therapy, 2023
- Target protein localization and its impact on PROTAC-mediated degradationCell Chemical Biology, 2022
- BacPROTACs mediate targeted protein degradation in bacteriaCell, 2022
- Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product functionCell Chemical Biology, 2021
- A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABLACS Chemical Biology, 2020